Rallybio Corp(RLYB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 3.43 | EPS (ttm) | 4.49 | Insider Own | 23.23% | Shs Outstand | 5.3M | Perf Week | -6.04% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | - | Insider Trans | 31.82% | Shs Float | 4.1M | Perf Month | -10.41% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 58.95% | Short Float | 0.99% | Perf Quarter | -3.26% |
| Income | 0.03B | P/S | 192.95 | EPS this Y | - | Inst Trans | -28.83% | Short Ratio | 2.73 | Perf Half Y | 71.6% |
| Sales | 0.00B | P/B | 0.89 | EPS next 5Y | - | ROA | 32.85% | Short Interest | 0.04M | Perf YTD | 180.75% |
| Book/sh | 17.31 | P/C | 0.91 | EPS past 3/5Y | 54.34% 24.69% | ROE | 34.52% | 52W High | -12.31% ($17.57) | Perf Year | 218.23% |
| Cash/sh | 16.84 | P/FCF | 2.68 | Sales past 3/5Y | - | ROIC | 29.05% | 52W Low | 319.88% ($3.67) | Perf 3Y | -52.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 281.1% | Gross Margin | 98.16% | Volatility(W/M) | 4.39% 2.43% | Perf 5Y | -89.21% |
| Dividend TTM | - | EV/Sales | -17.96 | Sales Y/Y TTM | -35.61% | Oper. Margin | -4659.22% | ATR (14) | 0.47 | Perf 10Y | - |
| Dividend Ex-Date | 2026/11/6 | Quick Ratio | 28.87 | EPS Q/Q | -116.77% | Profit Margin | 6177.42% | RSI (14) | 30.82 | Recom | 2.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 28.87 | Sales Q/Q | -100% | SMA20 | -7.01% ($16.57) | Beta | -0.74 | Target Price | $8 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -8.03% ($16.76) | Rel Volume | 3.49 | Prev Close | $15.99 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 268.75% 217.84% | SMA200 | 19.65% ($12.88) | Avg Volume(3M) | 0.02M | Price | $15.41 |
| IPO | 2021/7/29 | Option/Short | No/Yes | Trades | 526 | Volume | 52,343 | Change | -3.63% |
🧬 This is a US clinical-stage biotech company developing therapies for serious rare diseases. Headquartered in New Haven, Connecticut, it researches and develops antibody-based drug candidates, and as a small, focused organization with no product sales revenue yet, pipeline progress and collaboration agreements are the central drivers of its corporate value.
Over the past 1 year, on the higher side
12% below its 1-year high.
Traded more than usual. That is 349% of its average volume.
Ex-dividend date: November 6
7 days to go. Buy before this date to receive the dividend.
RLYB has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $343. Peers typically go for $1,433.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -89.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 59.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #378 of 594 in the industry
Based on market cap of $83M.
FAQ
What kind of company is RLYB?
RLYB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RLYB?
The market cap of RLYB is approximately $83M, ranking 4,584 within its sector.
What is the P/E ratio of RLYB?
RLYB has a P/E ratio of approximately 3.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RLYB?
RLYB has recorded a 52-week high of $17.57 and a low of $3.67.
